ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGIO Agios Pharmaceuticals Inc

29.29
0.00 (0.00%)
Pre Market
Last Updated: 04:05:56
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 28.00
Ask Price 32.00
News -
Day High

Low
19.795

52 Week Range

High
35.48

Day Low
Company Name Stock Ticker Symbol Market Type
Agios Pharmaceuticals Inc AGIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 29.29 04:05:56
Open Price Low Price High Price Close Price Prev Close
29.29
Trades Volume Avg Volume 52 Week Range
0 0 - 19.795 - 35.48
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 29.29 USD

Agios Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.65B 56.19M - 26.82M -352.09M -6.27 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Agios Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AGIO Message Board. Create One! See More Posts on AGIO Message Board See More Message Board Posts

Historical AGIO Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week30.7431.0428.9429.81714,271-1.45-4.72%
1 Month26.1935.4826.1931.42958,0723.1011.84%
3 Months24.2035.4820.9626.47874,4455.0921.03%
6 Months25.4535.4819.79524.75705,7543.8415.09%
1 Year23.2235.4819.79525.00564,2716.0726.14%
3 Years48.9662.15516.7532.29602,968-19.67-40.18%
5 Years65.2169.6416.7537.37636,730-35.92-55.08%

Agios Pharmaceuticals Description

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Your Recent History

Delayed Upgrade Clock